-

06:13:51 PM

IMRN Stock News

IMRN - Immuron Limited

01/25/23 6:00 AM

Nasdaq : IMRN

low float

Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today

RHEA-AI

neutral

01/18/23 5:00 AM

Nasdaq : IMRN

low float

US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone

Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study 157 participants successfully randomized into the Clinical Study Plans in place to enrol in 1302 healthy volunteers in total Infectious diarrhea is the most common illness reported by travelers & military personnel

RHEA-AI

neutral

01/17/23 7:10 AM

Nasdaq : IMRN

low float

Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is

RHEA-AI

very positive

12/23/22 6:00 AM

Nasdaq : IMRN

fda approvallow float

Immuron Receives FDA Approval for Travelan IND Application

Highlights: Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active Plans in place to initiate a Human clinical

RHEA-AI

neutral

12/05/22 6:00 AM

Nasdaq : IMRN

low float

Immuron Submits IND Application To FDA for Travelan

Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA Clinical Trial to examine a dosing regimen for Travelan more suited for use by the US military

RHEA-AI

neutral

11/16/22 7:00 AM

Nasdaq : IMRN

low float

Immuron completes strategic investment in leading gut health biotech Ateria Health

Highlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria

RHEA-AI

very positive

10/26/22 6:00 AM

Nasdaq : IMRN

conferenceslow float

Immuron CEO, Steven Lydeamore to present at AusBioInvest

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is

RHEA-AI

neutral

10/13/22 6:00 AM

Nasdaq : IMRN

low float

Immuron strategic investment in leading gut health biotech Ateria Health

Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Health is a

RHEA-AI

very positive

10/04/22 6:00 AM

Nasdaq : IMRN

clinical triallow float

Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron

Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron Executed Investigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Controlled Human Infection Model (CHIM) clinical trial in 60 healthy volunteers

RHEA-AI

neutral

08/29/22 7:00 AM

Nasdaq : IMRN

conferenceslow float

Immuron CEO, Steven Lydeamore, to host an investor webinar

Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast hosted

RHEA-AI

neutral